biotech investing argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update 26 February
biotech investing argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis 26 February
